Allarity Therapeutics, Inc. (ALLR)
(Delayed Data from NSDQ)
$0.64 USD
+0.06 (10.48%)
Updated May 22, 2024 04:00 PM ET
After-Market: $0.68 +0.04 (6.25%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALLR 0.64 +0.06(10.48%)
Will ALLR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALLR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLR
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
ALLR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ALLR
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Allarity regains compliance with Nasdaq minimum stockholder equity requirement
Allarity Therapeutics reports Q1 GAAP EPS of -$22.14
ALLR Stock Earnings: Allarity Therapeutics Reported Results for Q1 2024
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances